Skip to main content
NASDAQ:ALDX

Aldeyra Therapeutics Competitors

$12.48
-0.07 (-0.56 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.35
$12.75
50-Day Range
$10.44
$14.85
52-Week Range
$3.41
$15.95
Volume688,890 shs
Average Volume2.17 million shs
Market Capitalization$719.23 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86

Competitors

Aldeyra Therapeutics (NASDAQ:ALDX) Vs. TARO, INSM, PCRX, PTCT, MOR, and RCKT

Should you be buying ALDX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Aldeyra Therapeutics, including Taro Pharmaceutical Industries (TARO), Insmed (INSM), Pacira BioSciences (PCRX), PTC Therapeutics (PTCT), MorphoSys (MOR), and Rocket Pharmaceuticals (RCKT).

Aldeyra Therapeutics (NASDAQ:ALDX) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Aldeyra Therapeutics and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aldeyra TherapeuticsN/A-73.73%-52.74%
Taro Pharmaceutical Industries-45.94%10.36%8.38%

Insider & Institutional Ownership

61.3% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 11.2% of Taro Pharmaceutical Industries shares are owned by institutional investors. 15.0% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Aldeyra Therapeutics and Taro Pharmaceutical Industries, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aldeyra Therapeutics011002.91
Taro Pharmaceutical Industries00103.00

Aldeyra Therapeutics presently has a consensus price target of $26.1818, suggesting a potential upside of 109.79%. Taro Pharmaceutical Industries has a consensus price target of $81.00, suggesting a potential upside of 12.28%. Given Aldeyra Therapeutics' higher probable upside, equities research analysts clearly believe Aldeyra Therapeutics is more favorable than Taro Pharmaceutical Industries.

Valuation & Earnings

This table compares Aldeyra Therapeutics and Taro Pharmaceutical Industries' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aldeyra TherapeuticsN/AN/A$-60,830,000.00($2.05)-6.09
Taro Pharmaceutical Industries$644.77 million4.28$244.24 million$6.3511.36

Taro Pharmaceutical Industries has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Aldeyra Therapeutics has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Summary

Aldeyra Therapeutics beats Taro Pharmaceutical Industries on 7 of the 13 factors compared between the two stocks.

Aldeyra Therapeutics (NASDAQ:ALDX) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Valuation & Earnings

This table compares Aldeyra Therapeutics and Insmed's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aldeyra TherapeuticsN/AN/A$-60,830,000.00($2.05)-6.09
Insmed$136.47 million20.07$-254,340,000.00($3.01)-8.79

Aldeyra Therapeutics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aldeyra Therapeutics and Insmed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aldeyra TherapeuticsN/A-73.73%-52.74%
Insmed-145.14%-79.58%-31.14%

Insider & Institutional Ownership

61.3% of Aldeyra Therapeutics shares are owned by institutional investors. 15.0% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 4.6% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Aldeyra Therapeutics and Insmed, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aldeyra Therapeutics011002.91
Insmed00703.00

Aldeyra Therapeutics presently has a consensus price target of $26.1818, suggesting a potential upside of 109.79%. Insmed has a consensus price target of $53.5714, suggesting a potential upside of 102.46%. Given Aldeyra Therapeutics' higher probable upside, equities research analysts clearly believe Aldeyra Therapeutics is more favorable than Insmed.

Volatility & Risk

Aldeyra Therapeutics has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Insmed has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500.

Summary

Aldeyra Therapeutics beats Insmed on 9 of the 13 factors compared between the two stocks.

Aldeyra Therapeutics (NASDAQ:ALDX) and Pacira BioSciences (NASDAQ:PCRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Valuation and Earnings

This table compares Aldeyra Therapeutics and Pacira BioSciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aldeyra TherapeuticsN/AN/A$-60,830,000.00($2.05)-6.09
Pacira BioSciences$421.03 million6.48$-11,020,000.00$0.8672.07

Pacira BioSciences has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aldeyra Therapeutics and Pacira BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aldeyra TherapeuticsN/A-73.73%-52.74%
Pacira BioSciences29.95%10.71%4.88%

Insider and Institutional Ownership

61.3% of Aldeyra Therapeutics shares are held by institutional investors. 15.0% of Aldeyra Therapeutics shares are held by insiders. Comparatively, 5.8% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Aldeyra Therapeutics and Pacira BioSciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aldeyra Therapeutics011002.91
Pacira BioSciences04802.67

Aldeyra Therapeutics currently has a consensus price target of $26.1818, suggesting a potential upside of 109.79%. Pacira BioSciences has a consensus price target of $78.5833, suggesting a potential upside of 26.79%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Pacira BioSciences.

Volatility & Risk

Aldeyra Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.

Summary

Pacira BioSciences beats Aldeyra Therapeutics on 7 of the 13 factors compared between the two stocks.

Aldeyra Therapeutics (NASDAQ:ALDX) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Volatility & Risk

Aldeyra Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.

Insider and Institutional Ownership

61.3% of Aldeyra Therapeutics shares are held by institutional investors. 15.0% of Aldeyra Therapeutics shares are held by insiders. Comparatively, 7.0% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Aldeyra Therapeutics and PTC Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aldeyra TherapeuticsN/A-73.73%-52.74%
PTC Therapeutics-123.19%-76.10%-24.60%

Valuation and Earnings

This table compares Aldeyra Therapeutics and PTC Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aldeyra TherapeuticsN/AN/A$-60,830,000.00($2.05)-6.09
PTC Therapeutics$306.98 million8.79$-251,580,000.00($3.45)-11.10

Aldeyra Therapeutics has higher earnings, but lower revenue than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Aldeyra Therapeutics and PTC Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aldeyra Therapeutics011002.91
PTC Therapeutics05602.55

Aldeyra Therapeutics currently has a consensus price target of $26.1818, suggesting a potential upside of 109.79%. PTC Therapeutics has a consensus price target of $65.10, suggesting a potential upside of 70.02%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than PTC Therapeutics.

Summary

Aldeyra Therapeutics beats PTC Therapeutics on 10 of the 13 factors compared between the two stocks.

MorphoSys (NASDAQ:MOR) and Aldeyra Therapeutics (NASDAQ:ALDX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for MorphoSys and Aldeyra Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MorphoSys05402.44
Aldeyra Therapeutics011002.91

Aldeyra Therapeutics has a consensus target price of $26.1818, suggesting a potential upside of 109.79%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than MorphoSys.

Volatility & Risk

MorphoSys has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500.

Profitability

This table compares MorphoSys and Aldeyra Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MorphoSys8.76%4.51%2.25%
Aldeyra TherapeuticsN/A-73.73%-52.74%

Valuation and Earnings

This table compares MorphoSys and Aldeyra Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$80.43 million32.63$-115,380,000.00($0.91)-21.92
Aldeyra TherapeuticsN/AN/A$-60,830,000.00($2.05)-6.09

Aldeyra Therapeutics has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

3.1% of MorphoSys shares are held by institutional investors. Comparatively, 61.3% of Aldeyra Therapeutics shares are held by institutional investors. 15.0% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Aldeyra Therapeutics beats MorphoSys on 7 of the 13 factors compared between the two stocks.

Rocket Pharmaceuticals (NASDAQ:RCKT) and Aldeyra Therapeutics (NASDAQ:ALDX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and Aldeyra Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rocket PharmaceuticalsN/AN/A$-77,270,000.00($1.58)-26.34
Aldeyra TherapeuticsN/AN/A$-60,830,000.00($2.05)-6.09

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Rocket Pharmaceuticals has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500.

Profitability

This table compares Rocket Pharmaceuticals and Aldeyra Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rocket PharmaceuticalsN/A-35.81%-27.52%
Aldeyra TherapeuticsN/A-73.73%-52.74%

Analyst Ratings

This is a summary of current recommendations for Rocket Pharmaceuticals and Aldeyra Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rocket Pharmaceuticals011202.92
Aldeyra Therapeutics011002.91

Rocket Pharmaceuticals presently has a consensus price target of $59.1818, indicating a potential upside of 42.23%. Aldeyra Therapeutics has a consensus price target of $26.1818, indicating a potential upside of 109.79%. Given Aldeyra Therapeutics' higher possible upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Rocket Pharmaceuticals.

Insider and Institutional Ownership

61.3% of Aldeyra Therapeutics shares are owned by institutional investors. 41.4% of Rocket Pharmaceuticals shares are owned by company insiders. Comparatively, 15.0% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Rocket Pharmaceuticals beats Aldeyra Therapeutics on 7 of the 11 factors compared between the two stocks.


Aldeyra Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.14-0.1%$2.76 billion$644.77 million-10.29Upcoming Earnings
News Coverage
Insmed logo
INSM
Insmed
1.2$26.46-1.9%$2.74 billion$136.47 million-10.18Earnings Announcement
Analyst Report
High Trading Volume
Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.3$61.98-2.0%$2.73 billion$421.03 million21.82Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$38.29-1.2%$2.70 billion$306.98 million-5.48
MorphoSys logo
MOR
MorphoSys
0.3$19.95-2.0%$2.62 billion$80.43 million95.00Gap Down
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$41.61-1.1%$2.57 billionN/A-22.86Earnings Announcement
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.22-4.1%$2.45 billion$182.24 million-8.02Earnings Announcement
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$58.91-2.1%$2.43 billionN/A0.00
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.7$20.61-0.8%$2.40 billion$306.49 million23.16Earnings Announcement
Cryoport logo
CYRX
Cryoport
1.7$51.27-10.3%$2.34 billion$33.94 million-88.40Analyst Report
Analyst Revision
Gap Down
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$46.61-1.1%$2.33 billion$963.01 million14.48Earnings Announcement
Analyst Report
Analyst Revision
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.8$36.60-3.3%$2.28 billion$2.11 million-7.92Analyst Report
Analyst Revision
OPKO Health logo
OPK
OPKO Health
1.9$3.33-2.7%$2.23 billion$901.90 million-18.50Insider Buying
Xencor logo
XNCR
Xencor
1.6$37.92-1.8%$2.21 billion$156.70 million-27.09Analyst Upgrade
Analyst Revision
Organogenesis logo
ORGO
Organogenesis
1.0$17.18-4.3%$2.20 billion$260.98 million-286.33Earnings Announcement
Analyst Downgrade
Analyst Revision
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$132.71-0.1%$2.20 billionN/A-11.99Earnings Announcement
Analyst Revision
ALX Oncology logo
ALXO
ALX Oncology
1.9$54.68-10.8%$2.20 billionN/A0.00
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.7$27.92-2.9%$2.15 billion$103.54 million-20.99Earnings Announcement
Analyst Revision
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$57.01-0.0%$2.14 billionN/A-21.19Earnings Announcement
Analyst Report
Analyst Revision
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$65.90-0.3%$2.11 billionN/A-28.04Earnings Announcement
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$125.35-4.1%$2.09 billion$120.28 million-126.62Analyst Report
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.7$29.15-1.4%$2.07 billion$15 million-15.26Analyst Downgrade
Analyst Revision
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.93-2.1%$1.99 billion$410,000.00-6.07Earnings Announcement
Analyst Report
News Coverage
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$25.72-4.4%$1.98 billion$23.90 million-15.98Earnings Announcement
Analyst Revision
FibroGen logo
FGEN
FibroGen
1.8$21.13-4.6%$1.95 billion$256.58 million-8.10Earnings Announcement
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.98-6.2%$1.92 billion$34.51 million-17.93Analyst Report
Gap Down
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$33.01-1.6%$1.91 billion$25 million-6.60Analyst Report
Analyst Revision
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$20.67-4.4%$1.88 billionN/A-7.36Earnings Announcement
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$11.16-1.5%$1.80 billion$428.41 million16.17Earnings Announcement
Morphic logo
MORF
Morphic
1.5$49.25-2.7%$1.78 billion$16.98 million-31.57Analyst Report
Gap Down
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.32-2.3%$1.74 billion$26.87 million-12.73Earnings Announcement
Analyst Report
MacroGenics logo
MGNX
MacroGenics
1.4$28.94-5.6%$1.74 billion$64.19 million-9.25
Generation Bio logo
GBIO
Generation Bio
1.8$30.60-0.8%$1.73 billionN/A0.00News Coverage
Amarin logo
AMRN
Amarin
1.6$4.35-6.0%$1.71 billion$429.76 million-86.98Analyst Downgrade
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$24.75-1.5%$1.64 billionN/A-15.18Earnings Announcement
Analyst Downgrade
Analyst Revision
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$19.74-4.8%$1.63 billionN/A0.00
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.41-6.1%$1.60 billion$145.97 million-7.05Earnings Announcement
Analyst Upgrade
Analyst Revision
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
2.0$5.32-2.3%$1.60 billion$1.63 billion12.98Earnings Announcement
Analyst Upgrade
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.6$44.30-7.0%$1.57 billionN/A0.00Earnings Announcement
Insider Selling
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.9$29.43-0.2%$1.56 billion$392.76 million12.21Analyst Revision
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$27.13-4.3%$1.54 billionN/A0.00Earnings Announcement
Cassava Sciences logo
SAVA
Cassava Sciences
1.1$37.49-4.6%$1.50 billionN/A-156.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$21.69-0.4%$1.49 billion$2.34 million-9.19Analyst Report
Gap Down
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$42.07-6.9%$1.48 billionN/A0.00Gap Down
uniQure logo
QURE
uniQure
1.7$31.97-2.6%$1.47 billion$7.28 million-8.48Earnings Announcement
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$11.29-0.5%$1.45 billion$320,000.00-7.68
Kronos Bio logo
KRON
Kronos Bio
1.7$25.43-3.7%$1.43 billionN/A0.00Earnings Announcement
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.00-1.7%$1.40 billionN/A0.00Analyst Report
Gap Up
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.26-8.7%$1.37 billionN/A-2.95
This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.